Loading news...
Mirum Pharmaceuticals was profitable in the third quarter. However, top-line growth for the midcap biotech will slow this year.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) COO Peter Radovich sold 3,143 shares of the firm's stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $302,325.17. Following the sale, the chief operating officer directly owned 23,286 shares in
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CEO Christopher Peetz sold 6,831 shares of the business's stock in a transaction on Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $657,073.89. Following the sale, the chief executive officer directly owned 169,402 shares of the company's
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) SVP Jolanda Howe sold 842 shares of the firm's stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $80,991.98. Following the transaction, the senior vice president owned 3,700 shares in the
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CFO Eric Bjerkholt sold 1,053 shares of the company's stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $96.19, for a total transaction of $101,288.07. Following the transaction, the chief financial officer owned 43,741 shares in the
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) Director Patrick Heron purchased 131,425 shares of the firm's stock in a transaction on Friday, January 23rd. The stock was bought at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the acquisition, the director owned 459,010 shares in the company, valued
Guru Stock PicksChuck Royce has made the following transactions:Reduce in HIFS by 5.13%Add in DSP by 72.29%New position in ANDGStock News Social media addiction
Mirum Pharmaceuticals is at an inflection point. The company's sales are growing fast, led by the success of Livmarli.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) SVP Jolanda Howe sold 926 shares of the company's stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $86,423.58. Following the completion of the transaction, the senior vice president owned 3,042 shares in
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) CFO Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $132,621.93. Following the completion of the sale, the chief financial officer owned 42,127 shares in
Emerald Advisers LLC increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) by 20.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 369,600 shares of the company's stock after acquiring an additional 63,834 shares during the quarter. Emerald
CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
MIRM shares rise this week on strong preliminary 2025 sales, upbeat 2026 outlook, key pipeline goals and business updates.
Mirum Pharmaceuticals, Inc. (MIRM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Meta Platforms is an advertising juggernaut with tremendous growth potential in the AI glasses market. Micron Technology is a steal of a deal among AI stocks.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
A director at Mirum Pharmaceuticals sold 5,000 shares of the company for $400,000 on Dec. 22. The entire transaction was direct, involving the exercise of vested stock options, immediately sold as shares.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum.
ESCONDIDO, Calif.--(BUSINESS WIRE)--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS). MRM-3379 is an orally available, highly brain-penetrant, selective phosphodiestera.